克隆-话题@MedSci

#克隆#

209篇内容 | 3886人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1660248, encodeId=afbc166024828, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=CD47单克隆抗体初露锋芒！天镜生物多项研发管线产品齐头并进, objectType=article, longId=209745, objectId=fb33209e4510, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb33209e4510, replyNumber=0, likeNumber=73, createdTime=2021-06-09, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb33209e4510, moduleTitle=CD47单克隆抗体初露锋芒！天镜生物多项研发管线产品齐头并进, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb33209e4510)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660242, encodeId=9feb166024248, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=Lancet Neurol：Tau蛋白单克隆抗体Tilavonemab对进行性核上性麻痹治疗无效！, objectType=article, longId=207468, objectId=eaa720e4686f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eaa720e4686f, replyNumber=0, likeNumber=77, createdTime=2021-03-29, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eaa720e4686f, moduleTitle=Lancet Neurol：Tau蛋白单克隆抗体Tilavonemab对进行性核上性麻痹治疗无效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eaa720e4686f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660232, encodeId=1698166023269, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=阿斯利康将在COVID-19试验中测试长效抗体AZD7442（两种单克隆抗体的混合物）, objectType=article, longId=201925, objectId=8cbd20192559, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8cbd20192559, replyNumber=0, likeNumber=0, createdTime=2021-01-09, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cbd20192559, moduleTitle=阿斯利康将在COVID-19试验中测试长效抗体AZD7442（两种单克隆抗体的混合物）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8cbd20192559)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660239, encodeId=85331660239d6, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=Lancet Oncol：CD40激动性单克隆抗体APX005M联合化疗治疗转移性胰腺癌, objectType=article, longId=205427, objectId=c5f320542e03, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5f320542e03, replyNumber=0, likeNumber=72, createdTime=2021-07-26, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5f320542e03, moduleTitle=Lancet Oncol：CD40激动性单克隆抗体APX005M联合化疗治疗转移性胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5f320542e03)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660238, encodeId=bdf416602388e, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=美国肾脏护理（USRC）将在透析门诊对COVID-19患者进行单克隆抗体（Bamlanivimab）治疗, objectType=article, longId=205041, objectId=b2e520504164, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2e520504164, replyNumber=0, likeNumber=89, createdTime=2021-04-28, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2e520504164, moduleTitle=美国肾脏护理（USRC）将在透析门诊对COVID-19患者进行单克隆抗体（Bamlanivimab）治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2e520504164)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660258, encodeId=c4e51660258fe, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=Nat Med：Tau蛋白单克隆抗体gosuranemab治疗进行性核上性麻痹的安全性和有效性临床研究, objectType=article, longId=216025, objectId=5632216025b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5632216025b3, replyNumber=0, likeNumber=122, createdTime=2021-11-12, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5632216025b3, moduleTitle=Nat Med：Tau蛋白单克隆抗体gosuranemab治疗进行性核上性麻痹的安全性和有效性临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5632216025b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660235, encodeId=595e1660235d1, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=Blood：多发性骨髓瘤克隆进化和扩散的特征, objectType=article, longId=203510, objectId=b46920351040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b46920351040, replyNumber=0, likeNumber=81, createdTime=2021-09-06, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b46920351040, moduleTitle=Blood：多发性骨髓瘤克隆进化和扩散的特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b46920351040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660234, encodeId=6fcc16602345f, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=默克（Merck）、IAVI和印度血清研究所合作开发COVID-19单克隆抗体, objectType=article, longId=202471, objectId=94642024e127, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94642024e127, replyNumber=0, likeNumber=75, createdTime=2021-07-06, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94642024e127, moduleTitle=默克（Merck）、IAVI和印度血清研究所合作开发COVID-19单克隆抗体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94642024e127)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660252, encodeId=f424166025250, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=Celltrion发布抗COVID-19单克隆抗体治疗瑞丹维单抗(CT-P59)全球III期试验的阳性顶线结果, objectType=article, longId=212850, objectId=8a1421285025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a1421285025, replyNumber=0, likeNumber=77, createdTime=2022-06-02, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a1421285025, moduleTitle=Celltrion发布抗COVID-19单克隆抗体治疗瑞丹维单抗(CT-P59)全球III期试验的阳性顶线结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a1421285025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660225, encodeId=d2031660225a7, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=Science：CD20单克隆抗体治疗B细胞恶性肿瘤的奥秘, objectType=article, longId=199630, objectId=6d341996303b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d341996303b, replyNumber=0, likeNumber=81, createdTime=2020-12-30, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d341996303b, moduleTitle=Science：CD20单克隆抗体治疗B细胞恶性肿瘤的奥秘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d341996303b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660223, encodeId=7302166022389, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=Clinica Chimica Acta：乙型肝炎病毒基因型的抗乙型肝炎疫苗单克隆抗体的免疫反应模式, objectType=article, longId=199102, objectId=1814199102b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1814199102b3, replyNumber=0, likeNumber=0, createdTime=2020-12-03, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1814199102b3, moduleTitle=Clinica Chimica Acta：乙型肝炎病毒基因型的抗乙型肝炎疫苗单克隆抗体的免疫反应模式, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1814199102b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660250, encodeId=0a64166025004, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=JNNP:慢性炎性多发性神经根神经病中的寡克隆IgG带, objectType=article, longId=210168, objectId=59d1210168f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59d1210168f1, replyNumber=0, likeNumber=78, createdTime=2021-06-15, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59d1210168f1, moduleTitle=JNNP:慢性炎性多发性神经根神经病中的寡克隆IgG带, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59d1210168f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660228, encodeId=5b411660228fc, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=韩国MFDS批准抗COVID-19单克隆抗体CT-P59的II / III期关键试验, objectType=article, longId=200903, objectId=43d720090395, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43d720090395, replyNumber=0, likeNumber=81, createdTime=2021-06-04, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43d720090395, moduleTitle=韩国MFDS批准抗COVID-19单克隆抗体CT-P59的II / III期关键试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43d720090395)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660233, encodeId=cf8a166023383, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=Nature：Vir Biotechnology的增强型单克隆抗体可诱导抗病毒感染的CD8+T细胞应答, objectType=article, longId=201934, objectId=9da620193435, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9da620193435, replyNumber=0, likeNumber=68, createdTime=2020-11-18, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9da620193435, moduleTitle=Nature：Vir Biotechnology的增强型单克隆抗体可诱导抗病毒感染的CD8+T细胞应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9da620193435)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660247, encodeId=aac1166024eef, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=葛兰素史克（GSK）寻求COVID-19单克隆抗体VIR-7831的紧急授权, objectType=article, longId=209106, objectId=7c5620910665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c5620910665, replyNumber=0, likeNumber=71, createdTime=2022-01-03, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c5620910665, moduleTitle=葛兰素史克（GSK）寻求COVID-19单克隆抗体VIR-7831的紧急授权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c5620910665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660229, encodeId=e55d1660229d6, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=Science：癌旁正常上皮组织存在大量突变及克隆扩增，马兜铃酸强烈促进正常细胞DNA突变, objectType=article, longId=201648, objectId=0c702016480a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c702016480a, replyNumber=0, likeNumber=76, createdTime=2021-02-03, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c702016480a, moduleTitle=Science：癌旁正常上皮组织存在大量突变及克隆扩增，马兜铃酸强烈促进正常细胞DNA突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c702016480a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660227, encodeId=617a166022e5f, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=抗COVID-19单克隆抗体候选药物CT-P59：I期临床试验获得积极结果, objectType=article, longId=200591, objectId=c78820059127, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c78820059127, replyNumber=0, likeNumber=75, createdTime=2021-07-08, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c78820059127, moduleTitle=抗COVID-19单克隆抗体候选药物CT-P59：I期临床试验获得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c78820059127)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660237, encodeId=0cfc166023ed1, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, objectType=article, longId=204948, objectId=3cf1204948c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cf1204948c8, replyNumber=0, likeNumber=79, createdTime=2021-05-27, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cf1204948c8, moduleTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cf1204948c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660218, encodeId=de52166021852, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=创胜集团宣布其 Claudin18.2 人源化单克隆抗体新药 TST001 获得美国 FDA 许可开展临床试验, objectType=article, longId=192588, objectId=947f192588c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=947f192588c6, replyNumber=0, likeNumber=74, createdTime=2021-03-02, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=947f192588c6, moduleTitle=创胜集团宣布其 Claudin18.2 人源化单克隆抗体新药 TST001 获得美国 FDA 许可开展临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=947f192588c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660236, encodeId=a9101660236af, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, objectTitle=ASH 2020：抗CD117单克隆抗体JSP191用于治疗严重联合免疫缺陷病（SCID）, objectType=article, longId=204325, objectId=737c20432583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=737c20432583, replyNumber=0, likeNumber=62, createdTime=2021-03-28, rootId=0, userName=aids221, userId=596825099872, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=737c20432583, moduleTitle=ASH 2020：抗CD117单克隆抗体JSP191用于治疗严重联合免疫缺陷病（SCID）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=737c20432583)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

克隆

2020-05-29

aids221 (审核中...)

前往app查看评论内容

#克隆#

CD47单克隆抗体初露锋芒！天镜生物多项研发管线产品齐头并进

2021-06-09

aids221 (审核中...)

前往app查看评论内容

#克隆#

Lancet Neurol：Tau蛋白单克隆抗体Tilavonemab对进行性核上性麻痹治疗无效！

2021-03-29

aids221 (审核中...)

前往app查看评论内容

#克隆#

阿斯利康将在COVID-19试验中测试长效抗体AZD7442（两种单克隆抗体的混合物）

2021-01-09

aids221 (审核中...)

前往app查看评论内容

#克隆#

Lancet Oncol：CD40激动性单克隆抗体APX005M联合化疗治疗转移性胰腺癌

2021-07-26

aids221 (审核中...)

前往app查看评论内容

#克隆#

美国肾脏护理（USRC）将在透析门诊对COVID-19患者进行单克隆抗体（Bamlanivimab）治疗

2021-04-28

aids221 (审核中...)

前往app查看评论内容

#克隆#

Nat Med：Tau蛋白单克隆抗体gosuranemab治疗进行性核上性麻痹的安全性和有效性临床研究

2021-11-12

aids221 (审核中...)

前往app查看评论内容

#克隆#

Blood：多发性骨髓瘤克隆进化和扩散的特征

2021-09-06

aids221 (审核中...)

前往app查看评论内容

#克隆#

默克（Merck）、IAVI和印度血清研究所合作开发COVID-19单克隆抗体

2021-07-06

aids221 (审核中...)

前往app查看评论内容

#克隆#

Celltrion发布抗COVID-19单克隆抗体治疗瑞丹维单抗(CT-P59)全球III期试验的阳性顶线结果

2022-06-02

aids221 (审核中...)

前往app查看评论内容

#克隆#

Science：CD20单克隆抗体治疗B细胞恶性肿瘤的奥秘

2020-12-30

aids221 (审核中...)

前往app查看评论内容

#克隆#

Clinica Chimica Acta：乙型肝炎病毒基因型的抗乙型肝炎疫苗单克隆抗体的免疫反应模式

2020-12-03

aids221 (审核中...)

前往app查看评论内容

#克隆#

JNNP:慢性炎性多发性神经根神经病中的寡克隆IgG带

2021-06-15

aids221 (审核中...)

前往app查看评论内容

#克隆#

韩国MFDS批准抗COVID-19单克隆抗体CT-P59的II / III期关键试验

2021-06-04

aids221 (审核中...)

前往app查看评论内容

#克隆#

Nature：Vir Biotechnology的增强型单克隆抗体可诱导抗病毒感染的CD8+T细胞应答

2020-11-18

aids221 (审核中...)

前往app查看评论内容

#克隆#

葛兰素史克（GSK）寻求COVID-19单克隆抗体VIR-7831的紧急授权

2022-01-03

aids221 (审核中...)

前往app查看评论内容

#克隆#

Science：癌旁正常上皮组织存在大量突变及克隆扩增，马兜铃酸强烈促进正常细胞DNA突变

2021-02-03

aids221 (审核中...)

前往app查看评论内容

#克隆#

抗COVID-19单克隆抗体候选药物CT-P59：I期临床试验获得积极结果

2021-07-08

aids221 (审核中...)

前往app查看评论内容

#克隆#

患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究

2021-05-27

aids221 (审核中...)

前往app查看评论内容

#克隆#

创胜集团宣布其 Claudin18.2 人源化单克隆抗体新药 TST001 获得美国 FDA 许可开展临床试验

2021-03-02

aids221 (审核中...)

前往app查看评论内容

#克隆#

ASH 2020：抗CD117单克隆抗体JSP191用于治疗严重联合免疫缺陷病（SCID）

2021-03-28

科室
- - 订阅+
  - 更多科室
工具
服务